iBio (NASDAQ:IBIO) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of iBio (NASDAQ:IBIO) to a strong-buy rating in a research report report published on Thursday morning,Zacks.com reports.

A number of other equities research analysts also recently commented on IBIO. Weiss Ratings reiterated a “sell (d-)” rating on shares of iBio in a report on Monday, December 15th. Leerink Partnrs upgraded iBio to a “strong-buy” rating in a research report on Friday, October 17th. Finally, Wall Street Zen raised iBio from a “strong sell” rating to a “hold” rating in a research note on Sunday, November 16th. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy”.

iBio Stock Performance

IBIO opened at $1.98 on Thursday. The business’s 50 day simple moving average is $1.40. iBio has a fifty-two week low of $0.56 and a fifty-two week high of $6.89. The company has a market capitalization of $44.53 million, a P/E ratio of -1.42 and a beta of 1.13.

iBio (NASDAQ:IBIO) last released its earnings results on Wednesday, November 12th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04). The business had revenue of $0.10 million for the quarter.

About iBio

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.